European Network for Health Technology Assessment

European Network for Health Technology Assessment
Name	European Network for Health Technology Assessment
Abbreviation	EUnetHTA
Formation	2006
Type	Network
Headquarters	Brussels
Region served	Europe

European Network for Health Technology Assessment The European Network for Health Technology Assessment is a collaborative consortium linking European Commission, World Health Organization, Organisation for Economic Co-operation and Development, European Union institutions, and national agencies to coordinate Health Technology Assessment activities across Europe. It connects national bodies such as National Institute for Health and Care Excellence, Haute Autorité de Santé, and Instituto de Salud Carlos III with research centres like Karolinska Institutet and Università Vita-Salute San Raffaele to harmonize assessments of pharmaceuticals, medical devices, and public health interventions. The network supports policymaking by producing joint reports, methodological guidelines, and capacity-building initiatives involving stakeholders from Council of Europe, European Medicines Agency, and regional organizations.

History

EUnetHTA originated from discussions during meetings involving the European Commission Directorate-General for Health and Food Safety, the World Health Organization Regional Office for Europe, and national HTA agencies including Institute for Quality and Efficiency in Health Care and Finnish Medicines Agency. Early pilot projects drew on expertise from United Kingdom Department of Health, Ministry of Health and Social Affairs (Sweden), and Netherlands National Health Care Institute. The first formal consortium phase included partners such as Austrian Public Health Institute, Finnish Institute for Health and Welfare, and Portuguese National Institute of Health Dr. Ricardo Jorge, and was influenced by policy debates at the European Parliament and the Council of the European Union. Subsequent European Commission-funded Joint Actions integrated contributions from European Observatory on Health Systems and Policies, European Centre for Disease Prevention and Control, and academic institutions like University of Oxford and Maastricht University.

Structure and Governance

Governance is a multi-level arrangement linking national HTA bodies such as Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen and Swiss Agency for Therapeutic Products with European structures including the European Commission and consultative entities like European Patients' Forum and European Federation of Pharmaceutical Industries and Associations. A General Assembly of member organizations sets strategic priorities; a Coordination Team composed of agencies from Denmark, Germany, Italy, and Spain manages operations. Scientific Advisory Boards with experts from University College London, Charité – Universitätsmedizin Berlin, ETH Zurich, and University of Copenhagen provide methodological oversight. Working Groups liaise with regulators including European Medicines Agency and payers represented by bodies such as German Statutory Health Insurance and the National Health Service (England).

Mandate and Activities

EUnetHTA’s mandate covers joint production of relative effectiveness assessments, methodological guidance, and tools to assist decision-makers like ministries of health in France, Poland, Romania, and Greece. Activities include collaborative rapid assessments used by agencies such as National Institute for Health and Care Excellence, joint clinical assessments analogous to work by European Medicines Agency, and development of information models similar to those from International Classification of Diseases. The network runs pilots on topics including oncology treatments evaluated at centres such as Institut Gustave Roussy and European Organisation for Research and Treatment of Cancer, and device assessments aligning with standards from International Organization for Standardization and collaboration with European Committee for Standardization.

Methodologies and Standards

Methodological frameworks draw on health economics expertise from London School of Economics, clinical epidemiology from Harvard T.H. Chan School of Public Health, and biostatistics contributions akin to those of Cochrane Collaboration. EUnetHTA developed core models for outcome measures, evidence synthesis, and health economic modelling referencing practices at National Institute for Health and Care Excellence and decision-analytic methods used by Canadian Agency for Drugs and Technologies in Health. Standards for real-world evidence incorporate registries like European Medicines Agency’s ENCePP and collaborate with databases maintained by European Network of Centres for Pharmacoepidemiology and Pharmacovigilance and national cohorts from Sweden's National Patient Register.

Membership and Partnerships

Membership encompasses national HTA agencies from Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, and the United Kingdom institutions engaged pre- and post-Brexit. Partners include international organizations such as World Health Organization, OECD, and research funders like European Research Council, as well as patient groups such as EURORDIS and industry stakeholders including European Federation of Pharmaceutical Industries and Associations and medical device associations like MedTech Europe.

Funding and Legal Framework

Funding has combined European Commission Joint Action grants, contributions from national ministries of health in Germany, France, and Italy, and project-specific support from research programmes such as Horizon 2020 and Horizon Europe. Legal aspects intersect with EU regulation streams including the Regulation on Health Technology Assessment discussions in the European Parliament and instruments related to Cross-border Healthcare Directive. Agreements involve compliance with data protection rules from the European Data Protection Board and reference to case law from the Court of Justice of the European Union affecting information exchange and procurement.

Impact and Criticism

EUnetHTA influenced harmonization efforts informing policy in member states, contributing to shared assessments used by National Institute for Health and Care Excellence, Haute Autorité de Santé, and payer systems such as Sistem Informacyjny Ochrony Zdrowia in Poland. It facilitated capacity building through training with universities like Maastricht University and Karolinska Institutet and informed procurement in cross-border projects such as those coordinated by the European Commission and World Health Organization. Criticisms include concerns raised by stakeholders like European Patients' Forum and industry representatives over timeliness, resource allocation, and potential overlap with regulatory activities of European Medicines Agency; academic commentators from London School of Hygiene & Tropical Medicine and University of Oxford have debated methodological standardization versus national context sensitivity.

Category:Health technology assessment